The Hampton, UK-based company has followed an unusual funding model to date. The latest financing of £42m was led by Bridford Investments and focused on “a network of ultra-high net worth individuals, family offices and specialist health care investors.”
Karen Fallen, CEO of Touchlight DNA Services, explained this was how the biotech had been financed from the beginning, following...